Alterations in Breast Cancer Biomarkers Following Neoadjuvant Therapy
Introduction Biomarker changes in patients with residual disease (RD) after neoadjuvant systemic therapy (NAT) have unclear consequences. This study examined the prevalence of biomarker [hormone receptor (HR) and HER2] change and its effect on disease-free survival (DFS) and overall survival (OS). P...
Gespeichert in:
| Veröffentlicht in: | Annals of surgical oncology 2021-10, Vol.28 (11), p.5907-5917 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5917 |
|---|---|
| container_issue | 11 |
| container_start_page | 5907 |
| container_title | Annals of surgical oncology |
| container_volume | 28 |
| creator | Mohan, Srivarshini Cherukupalli Walcott-Sapp, Sarah Lee, Minna K. Srour, Marissa K. Kim, Sungjin Amersi, Farin F. Giuliano, Armando E. Chung, Alice P. |
| description | Introduction
Biomarker changes in patients with residual disease (RD) after neoadjuvant systemic therapy (NAT) have unclear consequences. This study examined the prevalence of biomarker [hormone receptor (HR) and HER2] change and its effect on disease-free survival (DFS) and overall survival (OS).
Patients and Methods
A total of 303 patients treated with NAT from 2008 to 2016 were identified from a prospective database. Biomarker status at diagnosis was determined and retested after NAT in patients with RD. DFS and OS were compared among three groups: no biomarker change, clinically insignificant change in either ER or PR without alteration in HR status, and clinically significant change in at least one biomarker with resultant change in HR or HER2 status. Subgroups with no change and HR change were examined [HR+HER2− no change, triple negative (TN) no change, HR+HER2− to TN, TN to HR+HER2].
Results
Overall, 61.4% of patients had RD. Of these, 32.8% had changes in at least one biomarker. At median follow up of 5.48 years, no biomarker change was associated with improved DFS compared with changes in HR or HER2 status (
p
=
0.043). In addition, no biomarker change (
p
=
0.005) and clinically insignificant changes in biomarker status (
p
=
0.019) were associated with improved OS compared with clinically significant changes in HR or HER2 status. Among subgroups, HR+HER2− to TN was associated with worse DFS (
p
=
0.029) and OS (
p
=
0.008) compared with HR+HER2− no change.
Conclusions
Among those with RD, biomarker status change was common and impacted survival in subgroups of HR+ or TN disease. Retesting biomarkers after NAT has prognostic implications. |
| doi_str_mv | 10.1245/s10434-021-09814-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2503672534</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2503672534</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-fbe13b28dd13aa264971f7c9115e71843ef4c7411a8276338989178383c050653</originalsourceid><addsrcrecordid>eNp9kDtPwzAYRS0EouXxBxhQJBaWgD-_M7ZVC0gVLGW23NQpKWlc7ATUf49LCkgMTLbsc-9nH4QuAN8AYfw2AGaUpZhAijMFLIUD1Acej5hQcBj3WKg0I4L30EkIK4xBUsyPUY9SyZTKRB-NB1VjvWlKV4ekrJOhtyY0ycjUufXJsHRr41-tD8nEVZX7KOtl8midWazad1M3yewlhjfbM3RUmCrY8_16ip4n49noPp0-3T2MBtM0p5I3aTG3QOdELRZAjSGCZRIKmWcA3EpQjNqC5ZIBGEWkoFRlKgOpqKI55lhweoquu96Nd2-tDY1elyG3VWVq69qgCcdUSBIVRPTqD7pyra_j6yIluYhtsKNIR-XeheBtoTe-jF_easB6J1l3knWUrL8ka4ihy311O1_bxU_k22oEaAeEeFUvrf-d_U_tJ-KdhM8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2575665314</pqid></control><display><type>article</type><title>Alterations in Breast Cancer Biomarkers Following Neoadjuvant Therapy</title><source>Springer Nature - Complete Springer Journals</source><creator>Mohan, Srivarshini Cherukupalli ; Walcott-Sapp, Sarah ; Lee, Minna K. ; Srour, Marissa K. ; Kim, Sungjin ; Amersi, Farin F. ; Giuliano, Armando E. ; Chung, Alice P.</creator><creatorcontrib>Mohan, Srivarshini Cherukupalli ; Walcott-Sapp, Sarah ; Lee, Minna K. ; Srour, Marissa K. ; Kim, Sungjin ; Amersi, Farin F. ; Giuliano, Armando E. ; Chung, Alice P.</creatorcontrib><description>Introduction
Biomarker changes in patients with residual disease (RD) after neoadjuvant systemic therapy (NAT) have unclear consequences. This study examined the prevalence of biomarker [hormone receptor (HR) and HER2] change and its effect on disease-free survival (DFS) and overall survival (OS).
Patients and Methods
A total of 303 patients treated with NAT from 2008 to 2016 were identified from a prospective database. Biomarker status at diagnosis was determined and retested after NAT in patients with RD. DFS and OS were compared among three groups: no biomarker change, clinically insignificant change in either ER or PR without alteration in HR status, and clinically significant change in at least one biomarker with resultant change in HR or HER2 status. Subgroups with no change and HR change were examined [HR+HER2− no change, triple negative (TN) no change, HR+HER2− to TN, TN to HR+HER2].
Results
Overall, 61.4% of patients had RD. Of these, 32.8% had changes in at least one biomarker. At median follow up of 5.48 years, no biomarker change was associated with improved DFS compared with changes in HR or HER2 status (
p
=
0.043). In addition, no biomarker change (
p
=
0.005) and clinically insignificant changes in biomarker status (
p
=
0.019) were associated with improved OS compared with clinically significant changes in HR or HER2 status. Among subgroups, HR+HER2− to TN was associated with worse DFS (
p
=
0.029) and OS (
p
=
0.008) compared with HR+HER2− no change.
Conclusions
Among those with RD, biomarker status change was common and impacted survival in subgroups of HR+ or TN disease. Retesting biomarkers after NAT has prognostic implications.</description><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1245/s10434-021-09814-1</identifier><identifier>PMID: 33748896</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Biomarkers ; Breast cancer ; Breast Oncology ; ErbB-2 protein ; Medicine ; Medicine & Public Health ; Oncology ; Surgery ; Surgical Oncology ; Survival</subject><ispartof>Annals of surgical oncology, 2021-10, Vol.28 (11), p.5907-5917</ispartof><rights>Society of Surgical Oncology 2021</rights><rights>Society of Surgical Oncology 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-fbe13b28dd13aa264971f7c9115e71843ef4c7411a8276338989178383c050653</citedby><cites>FETCH-LOGICAL-c375t-fbe13b28dd13aa264971f7c9115e71843ef4c7411a8276338989178383c050653</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1245/s10434-021-09814-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1245/s10434-021-09814-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33748896$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mohan, Srivarshini Cherukupalli</creatorcontrib><creatorcontrib>Walcott-Sapp, Sarah</creatorcontrib><creatorcontrib>Lee, Minna K.</creatorcontrib><creatorcontrib>Srour, Marissa K.</creatorcontrib><creatorcontrib>Kim, Sungjin</creatorcontrib><creatorcontrib>Amersi, Farin F.</creatorcontrib><creatorcontrib>Giuliano, Armando E.</creatorcontrib><creatorcontrib>Chung, Alice P.</creatorcontrib><title>Alterations in Breast Cancer Biomarkers Following Neoadjuvant Therapy</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><addtitle>Ann Surg Oncol</addtitle><description>Introduction
Biomarker changes in patients with residual disease (RD) after neoadjuvant systemic therapy (NAT) have unclear consequences. This study examined the prevalence of biomarker [hormone receptor (HR) and HER2] change and its effect on disease-free survival (DFS) and overall survival (OS).
Patients and Methods
A total of 303 patients treated with NAT from 2008 to 2016 were identified from a prospective database. Biomarker status at diagnosis was determined and retested after NAT in patients with RD. DFS and OS were compared among three groups: no biomarker change, clinically insignificant change in either ER or PR without alteration in HR status, and clinically significant change in at least one biomarker with resultant change in HR or HER2 status. Subgroups with no change and HR change were examined [HR+HER2− no change, triple negative (TN) no change, HR+HER2− to TN, TN to HR+HER2].
Results
Overall, 61.4% of patients had RD. Of these, 32.8% had changes in at least one biomarker. At median follow up of 5.48 years, no biomarker change was associated with improved DFS compared with changes in HR or HER2 status (
p
=
0.043). In addition, no biomarker change (
p
=
0.005) and clinically insignificant changes in biomarker status (
p
=
0.019) were associated with improved OS compared with clinically significant changes in HR or HER2 status. Among subgroups, HR+HER2− to TN was associated with worse DFS (
p
=
0.029) and OS (
p
=
0.008) compared with HR+HER2− no change.
Conclusions
Among those with RD, biomarker status change was common and impacted survival in subgroups of HR+ or TN disease. Retesting biomarkers after NAT has prognostic implications.</description><subject>Biomarkers</subject><subject>Breast cancer</subject><subject>Breast Oncology</subject><subject>ErbB-2 protein</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Survival</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp9kDtPwzAYRS0EouXxBxhQJBaWgD-_M7ZVC0gVLGW23NQpKWlc7ATUf49LCkgMTLbsc-9nH4QuAN8AYfw2AGaUpZhAijMFLIUD1Acej5hQcBj3WKg0I4L30EkIK4xBUsyPUY9SyZTKRB-NB1VjvWlKV4ekrJOhtyY0ycjUufXJsHRr41-tD8nEVZX7KOtl8midWazad1M3yewlhjfbM3RUmCrY8_16ip4n49noPp0-3T2MBtM0p5I3aTG3QOdELRZAjSGCZRIKmWcA3EpQjNqC5ZIBGEWkoFRlKgOpqKI55lhweoquu96Nd2-tDY1elyG3VWVq69qgCcdUSBIVRPTqD7pyra_j6yIluYhtsKNIR-XeheBtoTe-jF_easB6J1l3knWUrL8ka4ihy311O1_bxU_k22oEaAeEeFUvrf-d_U_tJ-KdhM8</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>Mohan, Srivarshini Cherukupalli</creator><creator>Walcott-Sapp, Sarah</creator><creator>Lee, Minna K.</creator><creator>Srour, Marissa K.</creator><creator>Kim, Sungjin</creator><creator>Amersi, Farin F.</creator><creator>Giuliano, Armando E.</creator><creator>Chung, Alice P.</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20211001</creationdate><title>Alterations in Breast Cancer Biomarkers Following Neoadjuvant Therapy</title><author>Mohan, Srivarshini Cherukupalli ; Walcott-Sapp, Sarah ; Lee, Minna K. ; Srour, Marissa K. ; Kim, Sungjin ; Amersi, Farin F. ; Giuliano, Armando E. ; Chung, Alice P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-fbe13b28dd13aa264971f7c9115e71843ef4c7411a8276338989178383c050653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biomarkers</topic><topic>Breast cancer</topic><topic>Breast Oncology</topic><topic>ErbB-2 protein</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mohan, Srivarshini Cherukupalli</creatorcontrib><creatorcontrib>Walcott-Sapp, Sarah</creatorcontrib><creatorcontrib>Lee, Minna K.</creatorcontrib><creatorcontrib>Srour, Marissa K.</creatorcontrib><creatorcontrib>Kim, Sungjin</creatorcontrib><creatorcontrib>Amersi, Farin F.</creatorcontrib><creatorcontrib>Giuliano, Armando E.</creatorcontrib><creatorcontrib>Chung, Alice P.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mohan, Srivarshini Cherukupalli</au><au>Walcott-Sapp, Sarah</au><au>Lee, Minna K.</au><au>Srour, Marissa K.</au><au>Kim, Sungjin</au><au>Amersi, Farin F.</au><au>Giuliano, Armando E.</au><au>Chung, Alice P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Alterations in Breast Cancer Biomarkers Following Neoadjuvant Therapy</atitle><jtitle>Annals of surgical oncology</jtitle><stitle>Ann Surg Oncol</stitle><addtitle>Ann Surg Oncol</addtitle><date>2021-10-01</date><risdate>2021</risdate><volume>28</volume><issue>11</issue><spage>5907</spage><epage>5917</epage><pages>5907-5917</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><abstract>Introduction
Biomarker changes in patients with residual disease (RD) after neoadjuvant systemic therapy (NAT) have unclear consequences. This study examined the prevalence of biomarker [hormone receptor (HR) and HER2] change and its effect on disease-free survival (DFS) and overall survival (OS).
Patients and Methods
A total of 303 patients treated with NAT from 2008 to 2016 were identified from a prospective database. Biomarker status at diagnosis was determined and retested after NAT in patients with RD. DFS and OS were compared among three groups: no biomarker change, clinically insignificant change in either ER or PR without alteration in HR status, and clinically significant change in at least one biomarker with resultant change in HR or HER2 status. Subgroups with no change and HR change were examined [HR+HER2− no change, triple negative (TN) no change, HR+HER2− to TN, TN to HR+HER2].
Results
Overall, 61.4% of patients had RD. Of these, 32.8% had changes in at least one biomarker. At median follow up of 5.48 years, no biomarker change was associated with improved DFS compared with changes in HR or HER2 status (
p
=
0.043). In addition, no biomarker change (
p
=
0.005) and clinically insignificant changes in biomarker status (
p
=
0.019) were associated with improved OS compared with clinically significant changes in HR or HER2 status. Among subgroups, HR+HER2− to TN was associated with worse DFS (
p
=
0.029) and OS (
p
=
0.008) compared with HR+HER2− no change.
Conclusions
Among those with RD, biomarker status change was common and impacted survival in subgroups of HR+ or TN disease. Retesting biomarkers after NAT has prognostic implications.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>33748896</pmid><doi>10.1245/s10434-021-09814-1</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1068-9265 |
| ispartof | Annals of surgical oncology, 2021-10, Vol.28 (11), p.5907-5917 |
| issn | 1068-9265 1534-4681 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2503672534 |
| source | Springer Nature - Complete Springer Journals |
| subjects | Biomarkers Breast cancer Breast Oncology ErbB-2 protein Medicine Medicine & Public Health Oncology Surgery Surgical Oncology Survival |
| title | Alterations in Breast Cancer Biomarkers Following Neoadjuvant Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A43%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Alterations%20in%20Breast%20Cancer%20Biomarkers%20Following%20Neoadjuvant%20Therapy&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Mohan,%20Srivarshini%20Cherukupalli&rft.date=2021-10-01&rft.volume=28&rft.issue=11&rft.spage=5907&rft.epage=5917&rft.pages=5907-5917&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1245/s10434-021-09814-1&rft_dat=%3Cproquest_cross%3E2503672534%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2575665314&rft_id=info:pmid/33748896&rfr_iscdi=true |